Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBITDA: 2023-2024

Historic EBITDA for Pyxis Oncology (PYXS) over the last 2 years, with Dec 2024 value amounting to -$77.2 million.

  • Pyxis Oncology's EBITDA fell 5.68% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.2 million for FY2024, which is 4.74% down from last year.
  • Latest data reveals that Pyxis Oncology reported EBITDA of -$77.2 million as of FY2024, which was down 4.74% from -$73.7 million recorded in FY2023.
  • Pyxis Oncology's 5-year EBITDA high stood at -$73.7 million for FY2023, and its period low was -$77.2 million during FY2024.
  • For the 2-year period, Pyxis Oncology's EBITDA averaged around -$75.5 million, with its median value being -$75.5 million (2023).
  • Data for Pyxis Oncology's EBITDA shows a maximum YoY decreased of 4.74% (in 2024) over the last 5 years.
  • Over the past 2 years, Pyxis Oncology's EBITDA (Yearly) stood at -$73.7 million in 2023, then fell by 4.74% to -$77.2 million in 2024.